Multidrug resistant and carbapenemase producing Enterobacteriaceae among patients with urinary tract infection at referral Hospital, Northwest Ethiopia by Setegn Eshetie et al.
Eshetie et al. Antimicrobial Resistance and Infection Control  (2015) 4:12 
DOI 10.1186/s13756-015-0054-7RESEARCH Open AccessMultidrug resistant and carbapenemase
producing Enterobacteriaceae among patients
with urinary tract infection at referral Hospital,
Northwest Ethiopia
Setegn Eshetie1, Chandrashekhar Unakal2, Aschalew Gelaw2, Birhanu Ayelign3, Mengistu Endris2
and Feleke Moges2*Abstract
Background: Updates on the epidemiology of antibiotic resistance bacterial pathogens is important. This is
because the spread of multidrug resistant enterobacteriaceae (MDRE) and recently carbapenemase producing
enterobacteriaceae (CPE) have emerged as a major public health concern in patients with urinary tract infections
(UTIs). This study is therefore, aimed to assess the prevalence and associated risk factors of MDR and CPE among
patients with UTIs.
Methods: A cross sectional study was conducted among 442 symptomatic UTI suspected patients. Data on
socio-demographic characteristics, clinical information and possible risk factors were collected using structured
questionnaire. Early morning mid-stream urine samples were collected and processed to characterize bacterial
isolates. Disk diffusion method was used to determine the antibiotic susceptibility patterns of isolates. Carbapenemase
producing strains were detected using CHROMagar KPC medium. Data were entered and analyzed using SPSS version 20.
P-value <0.05 was considered as statistical significant.
Results: Among 442 patients enrolled a total of 183 Enterobacteriaceae were recovered. Of these isolates; 160 (87.4%)
were MDRE; the most common isolates were K. pneumoniae and E.coli. Five (2.73%) of the isolates were found to be
carbapenemase producers and all of CPE strains were 100% ESBL producers. Significant drug resistances were
observed among CPE compared to other MDRE, low resistance rates were noted to ciprofloxacin (20%). Being
female (OR 4.46; P = 0.018), age (OR 1.08; P = 0.001), hospitalization (OR 5.23; P = 0.006), and prior antibiotic use
(OR 3.98; P = 0.04) were associated risk factors for MDRE.
Conclusion and recommendation: High rates of MDR (87.4%) were observed among enterobacteriaceae
uropathogens; K. pneumoniae and E.coli were the principal MDR isolates. Overall prevalence of CPE was 2.73%
and all of these strains were 100% ESBL producer. Attributing risk factors for MDR UTIs were found to be sex
(female), age, hospitalization, and history of antibiotic therapy. Therefore, efforts should be made to reduce
patient hospital stay and maximize rational use of drugs. Additional and vigorous investigation especially on
CPE should be encouraged.
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Urinary tract infections (UTIs) are one of the most com-
mon infectious diseases ranking next to upper respiratory
tract infection. Urinary tract infections are often associated
with significant morbidity and mortality. Worldwide, about
150 million people are diagnosed with UTI each year, cost-
ing the global economy in excess of 6 billion dollars [1]. In
developing countries, including Ethiopia, the facilities for
urine culture and antimicrobial susceptibility testing are still
not sufficiently available, leading to improper diagnosis and
irrational antibiotic treatment of UTI, which expedites the
emergence of multidrug resistant (MDR) strains [2]. Gram
negative bacteria, especially the family enterobacteriaceae
are the common cause of both community and hospital
acquired UTIs. Escherichia coli and Klebsiella pneumo-
niae are most commonly implicated among patients
with UTI [3,4].
Previously, the emergences of MDR among enterobac-
teriaceae were mainly due to the production of enzymes,
such as pencillinases, cephalosorinases, and extended
spectrum β-lactamase (ESBL). However, recently carba-
penemase production is one of the main mechanisms in
the occurrence of drug resistance in the family of en-
terobacteriaceae. Carbapenemase producing enterobac-
teriaceae (CPE) are difficult to treat because they have
high levels of resistance to antibiotics, which capable of
break down all β-lactam agents including carbapenems
and make it ineffective. Carbapenem such as imipenem,
meropenem, ertapenem, & doripenem are considered as
the last resort antibiotics to treat ESBL producing en-
terobacteriaceae [5,6].
Currently, increased burden of MDRE causing UTI
compounded by harboring carbapenem resistance genes
mainly among E. coli and K. pneumonia. These strains
become a serious threat to public health, associated with
high mortality rates and have the potential to spread widely.
Infections are difficult, and in some cases impossible to
treat and have been associated with mortality rates up to
50%. Due to the movement of patients throughout the
health care system, if CPE is a problem in one facility, then
typically they are a problem in other facilities in the region
as well. Carbapenemase producing enterobacteriaceae are
mostly endemic in specific geographical regions, but re-
ports of their spread into other geographical locations are
point of grave concern these days [5,7].
The aetiology of UTI and the antibiotic resistance of
uropathogens have been changing over the past years,
both in community and health care associated infections.
Current knowledge on the burden and antimicrobial
susceptibility pattern of the enterobacteriaceae isolates is
essential for appropriate therapy, since those groups of
bacteria are the main cause of UTIs and possess several
mechanisms to dismantle currently available antibiotics
including carbapenems and the condition in Ethiopia isnot yet assessed. Therefore, the objective of this study
was aimed to determine the prevalence and risk factors
of MDR and CPE producing strains among patients with
UTI at the University of Gondar Hospital, Ethiopia.
Materials and methods
Study area
The study was conducted at the University of Gondar
Hospital. It is referral hospital that provides services to
over 5 million inhabitants in the Northwest, Ethiopia. The
hospital has an accredited referral level laboratory with 7
sections and a separate reception room. Microbiology sec-
tion is one of the principal area, it is estimated that 9,600
samples delivered per annum to this working area. In this
section, culturing is one of the main activities, mainly
applicable for bacterial isolation and identification.
Study design, participants and data collection
A cross-sectional study was conducted from February to
May 2014. A total of 442 patients with symptomatic UTI
were selected from both in and out-patients using system-
atic random sampling technique. Socio-demographic char-
acteristics such as gender, age, residence, educational
status and history of travel were gathered from eligible pa-
tients. Clinical features such as history of hospitalization,
ICU admission, prior antibiotic use, prior UTI and chronic
diseases, pregnancy status, presence of urinary catheter
and mechanical ventilation were also collected. Moreover,
after instructing how to collect urine specimen, about
20 ml of a clean catch morning mid-stream urine was col-
lected from each patient [8] using a sterile screw-capped,
wide-mouth container and labeled with the unique sample
number, date and time of collection.
Isolation and identification of enterobacteriaceae
Urine specimens were directly inoculated on 5% Sheep
blood agar and incubated at 37°C for 24 hours. Urine cul-
ture was considered as positive, if it contains ≥105 cfu/ml.
Enterobacteriaceae from positive urine cultures were identi-
fied by their characteristic appearance on the media, gram
staining reaction, by the pattern of biochemical profiles
using standard procedures. Biochemical tests such as indole
production, sugar fermentation, H2S and gas production,
citrate utilization, motility test, urease test, oxidase, were
used to identify enterobacteriaceae isolates [8].
Susceptibility and carbapenemase testing
Antibiotic susceptibility was performed by employing
Kirby Bauer disk diffusion method using Mueller Hinton
agar (Oxoid) in accordance with the guidelines of clinical
and laboratory standards institute [9]. Enterobacteriaceae
were tested against the following antibiotic disks (Oxoid):
cefotaxime (CTX; 30 μg), ceftriaxone (CTR; 30 μg), cefe-
pime (CPM; 30 μg), ceftazidime (CAZ; 30 μg), cefpodoxime
Table 1 Socio-demographic characteristics of UTI
suspected patients at the University of Gondar Hospital,
February to May 2014 (N = 442)
Variables Frequency Percentage
Sex Male 160 36.2
Female 282 63.8





Residence Rural 252 57
Urban 190 43
Educational status Illiterate 196 44.3
Primary school 90 20.4
Secondary school 69 15.6
Diploma and Above 87 19.7
Sender of the patient Outpatient 212 48
Inpatient 230 52
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30 μg), chloramphenicol (C; 30 μg), amoxicillin-calvulanic
acid (AMC; 30 μg), naldixic acid (NA; 30 μg), gentamycin
(GEN; 10 μg), ampicillin (AMP; 10 μg) and trimethoprim-
sulfamethoxazole (SXT; 25 μg). After incubation of plates
at 37°C for 24 hours, diameters of zone of inhibition were
measured. Bacteria classified as susceptible, intermediate
and resistant strains according to the criteria of the clinical
and laboratory standards institute [9].
After antimicrobial susceptibility testing, all MDRE
(resistance to 2 or more classes of antibiotics) isolates
were collected and sub-cultured on CHROMagar TM
KPC agar to determine carbapenemase production. After
overnight incubation (24 hr), carbapenemase producing
isolates were assessed by visualizing colonies with typical
coloring characteristics. Carbapenemase producing E. coli
developed dark pink to reddish colony features, while
other enterobacteriaceae isolates produced metallic blue
colonies [10]. Those Carbapenemase producing colonies
with metallic blue color were further identified following
different classical biochemical tests (. Besides, all CPE
strains were tested whether they are extended spectrum
beta- lactamase (ESBL) producer or not using CHROM
agar ESBL medium.
Quality control
All materials, equipment and procedures were adequately
controlled. Culture media were tested for sterility and
performance. Pre-analytical, analytical and post-analytical
stages of quality assurance that are incorporated in stand-
ard operating procedures of the microbiology laboratory
were strictly followed. Standard strains of E.coli® ATCC
25922 (positive control) and S. aureus ATCC® 25923
(negative control) were used to control the performance
of CHROMagar TM KPC medium and other media. To
standardize the inoculum density of bacterial suspen-
sion for a susceptibility test, 0.5 McFarland standards
was used [9,10].
Ethical consideration
This study was approved by research and ethics committee
of School of Biomedical Laboratory Sciences, University of
Gondar, Ethiopia. Informed written consent was also ob-
tained from patients and/or guardians after explaining the
objective of the study. The laboratory results were commu-
nicated with the physicians for better management of the
patients.
Data analysis and interpretation
Data were collected, summarized and analyzed using SPSS
version 20 software and results were presented through
tables, pie charts and graphs. Associations were measu-
red using chi-square test, binary logistic regression.
P-values < 0.05 were considered as statistically significant.Results
Socio-demographic characteristics
A total of 442 patients with symptomatic UTI were en-
rolled in this study to investigate prevalence and associ-
ated risk factors of MDRE and CPE. Majority of the
participants were females 282 (63.8%). The mean age of
patients was 37.05 ± 10.5 years, 86 (19.5%) of the pa-
tients were younger than 16 years, and 73 (16.5%) were
older than 60 years. Two hundred fifty two (57.0%) of
patients were rural residents, and majority, 286 (64.7%)
of study participants had educational level of elementary
school and below (Table 1).
Multidrug resistance and carbapenemase producing
enterobacteriaceae in UTI suspected patients
Among study participants, 183 (41.4%) patients had
positive urine culture with a single non-duplicate isolates
of enterobacteriaceae. The most common isolates were
E.coli 112 (61.2%) followed by K. pneumoniae 29 (15.8%)
and E. aerogenes 13(7.1%) (Table 2). The isolates were
tested for antimicrobial susceptibility, 160 (87.4%, 95%
CI; 82–92.3%) of them showed resistance to two or more
classes of antibiotics. Among MDR strains, only 1 (0.6%)
isolate was resistant to 2 classes of antibiotics, the rest
159 (99.4%) were resistant to three or more classes of
antibiotics. Result of drug resistance patterns compared
within species showed that, 28 (95.6%) of K. pneumoniae
and 104(92.9%) of E. coli were MDR isolates (Table 2).
Of the 183 enterobacteriaceae isolates, 160 (87.4%)
were MDR strains, and these strains were tested for car-
bapenemase production by using phenotypic methods
Table 2 Multidrug resistance pattern of enterobacteriaceae among UTI suspects at the University of Gondar Hospital,
February to May 2014
Isolates Degree of resistance Total MDR
isolates (≥R2)R0 R1 R2 R3 R4 R5 R6 R7 R8 ≥R9
E. coli (N = 112) 2 (1.8) 6 (5.4) __ 5 ( 4.5) 28 (25) 24 (21.4) 32 (28.6) 9 (8.0) 4 (3.6) 2 (1.8) 104 (92.9)
K. pneumoniae (N = 29) __ 1 (3.4) __ 3 (10.3) 5 (17.2) 6 (20.7) 4 (13.8) 3 (10.3) 4 (13.8) 3 (10.3) 28 (95.6)
Enterobacter spp. (N = 16) 2 (12.5) 1 (6.3) __ 1 (6.3) 2 (12.5) 3 (18.8) 5 (31.3) 1 (6.3) __ 1 (6.3) 13 (81.3)
Citrobacter spp. (N = 6) 1 (16.7) __ 1 (16.7) __ 1 (16.7) __ 2 (33.3) __ 1 (16.7) __ 5 (83.3)
Proteus spp. (N = 9) 5 (55.6) 3 (33.3) __ ___ ___ 1 (11.1) ___ __ __ __ 1 (11.1)
Other Klebsiella spp. (N = 11) __ 2 (18.2) __ __ ___ 3 (27.3) 3 (27.3) 1 (9.1) 1 (9.1) 1 (9.1) 9 (81.8)
Total (N = 183) 10 (5.5) 13 (7.1) 1 (0.5) 9 (4.9) 36 (19.7) 37 (20.2) 46 (25.1) 14 (7.7) 10 (5.5) 2 (1.1) 160 (87.4)
Note: Data are in number (%) unless otherwise indicated.R0: susceptible to all antibiotics, R1-8: resistance to 2, 3, 4, 5, 6, 7, and 8 antibiotics, ≥R9: resistance to 9 or
more antibiotics, ≥R2: resistance to 2 or more antibiotics.
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were found to be CPE producers, notably E.coli (2), K.
pneumoniae (2) and E. aerogenes (1). All of the isolates
were from hospital admitted patients. The overall
prevalence of CPE was 2.73% (95%CI; 0.5-5.5%) among
all isolates and 3.1% among MDRE isolates. Besides, all
CPE strains were 100% ESBL producer, which were
demonstrated by using phenotypic methods (CHRO-
Magar ESBL media).
Rate of resistance for different antibiotics tested in MDRE
and CPE Isolates
The overall resistance profile of MDRE isolates are
shown in Table 3. High resistance rate were observed to
ampicillin (97.5%) followed by cotrimoxazole (64.4%),
and chloramphenicol (61.2%). Whereas, ciprofloxacin,
cefepime, and ceftriaxone had an overall resistance rates
of 2.5%, 10.6%, and 11.9%, respectively. Species specific
antibiotic resistance rates revealed that more than 55%Table 3 Antibiotic resistance patterns of MDRE among study
May 2014
MDR isolates Antibiotics
CTX CAZ CTR CPD CPM CIP
E.coli (N = 104) 25 (24.0) 58 (55.8) 12 (11.5) 43 (41.3) 9 (8.7) 1 (1)
K. pneumoniae
(N = 28)
8 (28.6) 16 (57.1) 5 (17.9) 18 (64.3) 4 (14.3) 3 (10.7)
K. ozaenae
(N = 6)
1 (16.7) 4 (66.7) 0 3 (50) 0 0
E. aerogenes
(N = 12)
4 (33.3) 7 (58.3) 2 (16.7) 5 (41.7) 3 (25) 0
Citrobacter spp
(N = 5)
1 (20) 2 (40) 0 1 (20) 0 0
*Others (N = 5) 2 (40) 3 (60) 0 1(20) 1(20) 0
Total MDRE
N = 160 (87.4%)
40 (25) 90 (56.2) 19 (11.9) 71 (44.4) 17 (10.6) 4 (2.5)
Note: Data are in number (%) unless otherwise indicated. *Others = K. oxytoca (N =
CTX: Cefotaxime, CAZ: Ceftazidime, CTR: Ceftriaxone, CPD: Cefpodoxime, CPM: Cefe
Chloramphenicol, NA: Naldixic acid, GEN: Gentamycin, AMC: Amoxicillin-Calvulanic aof E.coli isolates were resistant to ceftazidime, gentamycin,
chloramphenicol, cotrimoxazole, and ampicillin and low
rates of resistance were observed in ciprofloxacin (1%),
cefepime (8.7%) and ceftriaxone (11.5%). Over 60% of
K. pneumoniae were exhibited resistance to amoxicillin-
calvulanic acid, chloramphenicol, cefpodoxime, and
ampicillin, relatively low resistance rates were observed
to ciprofloxacin (10.7%), cefepime (14.3%), and ceftriax-
one (17.9%).
The overall resistance pattern of CPE isolates are sum-
marized in Figure 1. All isolates were 100% resistant to cef-
otaxime, cefpodoxime, cotrimoxazole, chloramphenicol,
ampicillin, and amoxicillin-calvulanic acid. However, only
20% of strains were resistant to ciprofloxacin. The overall
antibiotic resistance rates of CPE isolates were significantly
higher than other MDRE strains for more than half of
tested antibiotics including cefotaxime (100% versus 22.6%;
P < 0.001), ceftriaxone (60% versus 10.3%; P = 0.001), cefpo-
doxime (100% versus 42.6%; P = 0.011). On the other handparticipants: University of Gondar Hospital, February to
TE SXT C AMP NA GEN AMC
49 (47.1) 72 (69.2) 61 (58.7) 103 (99) 19 (18.3) 59 (56.7) 47 (45.2)
15 (53.6) 14 (50) 18 (64.3) 26 (92.9) 7 (25) 16 (57.1) 17 60.7)
4 (66.7) 5 (83.3) 5 (83.3) 6 (100) 2 (33.3) 4 (66.7) 5 (83.3)
5 (41.7) 5 (41.7) 7 (58.3) 12 (100) 2 (16.7) 7 (58.3) 9 (75)
4 (80) 3 (60) 4 (80) 4 (80) 1 (20) 4 (80) 2 (40)
2(40) 4 (80) 3(60) 5(100) 1(20) 4(80) 1(20)
79 (49.4) 103 (64.4) 98 (61.2) 156 (97.5) 32 (20) 94 (58.8) 81 (50.6)
3); E. cloacae (N = 1); P. vulgaris (N = 1).
pime, CIP: Ciprofloxacin, TE: Tetracycline, SXT: Cotrimoxazole, C:
cid.
scitoibitnA
CTX CAZ CTR CPD CPM CIP TE SXT C AMP NA GEN AMC 








































Note that: a: compared between CPE and other MDRE 
CTX: Cefotaxime, CAZ: Ceftazidime, CTR: Ceftriaxone, CPD: Cefpodoxime, CPM: Cefepime, CIP:  Ciprofloxacin, TE: 
Tetracycline, SXT: Cotrimoxazole, C: Chloramphenicol, NA: Naldixic acid, GEN: Gentamycin, AMC: Amoxicillin-Calvulanic acid. 
Figure 1 Antibiotic resistance rate of CPE isolates compared to other MDRE among study participants: University of Gondar Hospital, February to
May 2014.
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ceftazidime, tetracycline, cotrimoxazole, chloramphenicol,
ampicillin, and gentamycin were not statistically signifi-
cant compared to other MDRE isolates.
Risk factors for MDRE and CPE among study participants
Risk factors associated with MDRE UTIs were analyzed
by comparing patients with and without MDRE UTIs.
Bivariate analysis showed that, age, hospitalization for
the last 12 months, prior urinary tract infection for the
past 12 months, prior antibiotic use for the past 6 months
were associated with MDRE infections. In the analysis of
multivariate logistic regression, independent risk factors for
MDRE were prior antibiotic use, and hospitalization since
the past 12 months, age, and sex (female) (Table 4).
Discussion
The overall prevalence of MDR among enterobacteriaceae
isolates identified from patients with symptomatic UTI was
87.4% (95% CI; 82–92.3%), which is similar with the results
from previous study in Gondar (85.5%) and Mozambique
(88.2%) [11,12] while it was higher than reports from other
study in Ethiopia: Gondar (68%), and Dessie (74.6%) [13,14]
and many other countries, such as USA (19.1%), Belgium
(62%), and Italy (62%), Nepal (40.1%, 64.04%) [15-19]. How-
ever, it was lower than reports from different parts ofEthiopia such as Gondar (93.5%), Bahirdar (95.6%), and
Jimma (100%) [20-22]. The variation in prevalence of
MDRE isolates could be due to increase trend of MDR
strains with time, difference in study period and study
population.
The present study showed that, K. pneumoniae
(95.6%) and E.coli (92.9%) were found to be the principal
MDR isolates. Although the rate of proportion of MDR
is different in different area similar group of bacteria
were reported in Bahirdar, Ethiopia E.coli (94.6%) & K.
pneumoniae (80%) [21] and Nepal, E.coli (74%) and K.
pneumoniae (44%) and Dakar, E. coli and K. pneumoniae
(89%) [23] were the predominant MDR uropathogens
[19]. These pathogens are the most common isolates in
both hospital and community acquired urinary tract in-
fections. Besides, these bacteria are frequently difficult to
treat because of both their intrinsic and acquired resist-
ance to multiple groups of antimicrobial agents [3,4].
Among 183 enterobacteriaceae isolates, 5(2.73%) were
found to be carbapenemase producers. Comparable re-
sult were reported in studies from Morocco (2.8%) [24],
Bangladesh (4.8%) [25], Taiwan (2.5%) [26], Belgium
(3.5%) [27], and India (5.4%) [28]. However, this was
lower than from studies in Pakistan (8.6%) [29], Turkey
(10.9%) [30], India (12.9%) [31], Nigeria (14%, 33.5%)
[32,33], Iran (14.5%) [34], and USA (21%) [35]. The
Table 4 Risk factors associated with MDRE among UTI suspected patients at the University of Gondar Hospital,
February to May 2014
Risk factors MDRE Bivariate analysis Multivariable analysis
Yes (N = 160) No (N = 23) COR (95% CI) P-value AOR (95% CI) P-value
Sex
Female 106 12 1.79 (0.75 – 4.34) 0.191 4.46 (1.29 – 15.35) 0.018
Male 54 11 1 1
Age (years)
Mean age 38.5 13.2 1.08 (1.05 - 1.12) <0.001 1.08 (1.03 – 1.13) 0.001
Hospitalization
Yes 114 9 3.86 (1.56 – 9.53) 0.003 5.22 (1.59 – 17.17) 0.006
No 46 14 1 1
Prior UTI
Yes 65 4 3.25 (1.06 – 9.99) 0.040 2.41 (0.56 – 10.34) 0.239
No 95 19 1 1
Prior antibiotic use
Yes 129 7 9.51 (3.60 – 25.11) < 0.001 3.98 (1.056 – 14.97) 0.041
No 31 16 1 1
Note that: COR: crude odds ratio, AOR: adjusted odds ratio, CI: confidence interval.
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may be due to trends in the utilization of carbapenems
and other broad spectrum antibiotics, cultural/traditional
relationships, cross boarder transfer of patients with other
countries of high prevalence. Additionally, difference in
target population, sample size and methodological vari-
ability could bring variation in the epidemiology of CPE.
Moreover, according to World Health Organization
(WHO) 2014 report [36], the epidemiology of CPE has
not well studied in developing countries, therefore the
report insisted that integrated surveillance program and
involvement of very active investigation have to be maxi-
mized in order to know the extent of resistant strains in
these countries. Even though carbapenems drugs are not
formally introduced in to Ethiopia, as the report claimed
that increase international travel, globalization and mi-
gration might have contributing role in the dissemin-
ation of resistant strains from potentially risk countries
[36]. Especially, in this study area; there is high tourist
flow, and many of residences have relatives from abroad,
which may have an impact on the emergence of carbape-
nemase producing strains in this locality, particularly.
All carbapenemase producing isolates were from hospital
admitted patients. This was supported by the fact that inpa-
tients admitted to critical care units for treatment of acute
emergencies and chronic diseases are especially liable to get
CRE infections because of the presence of highly resistant
organisms available in an environment and selective pres-
sure on them due to overuse of antibiotics [37].
In the present study K. pneumoniae, E.coli, and E.
aerogenes were carbapenemase producers. This resultwas supported by the reports from European Antimicrobial
Resistance Surveillance Network (EARS-Net) that many of
carbapenemase producers were K. pneumoniae followed by
E.coli and Enterobacter spp., [38]. The same situations were
also notified in finding from Turkey and Morocco indicated
that K. pneumoniae were the principal isolate followed by
E.coli and K. oxytoca [30,35]. On the other hand, a study
from Nigeria demonstrated that E.coli was the main carba-
penemase producer followed by Proteus spp. and K. pneu-
moniae [32]. The variation among studies with regard to
the proportion of carbapenemase producing isolates; could
be due to difference in geographical distribution of isolates,
target population, sample size, and methodology used in
each investigation.
In Bivariate analysis, age (years), hospitalization within
the past 12 months, prior antibiotic therapy in the past
6 months, and prior UTI in the past 12 months were asso-
ciated with MDRE UTI in this study. Likewise, in multi-
variable analysis, age, being female, hospitalization within
the past 12 months, and prior antibiotic use in the past
6 months were the independent risk factors for MDRE
UTIs. The same result was documented in a study done
from USA [15]. However, additional risk factors like health
care associated risks (use of urinary catheter, mechanical
ventilation, and hemodialysis) were identified in the
former study, which were not indicated in this study.
Conclusion and recommendation
High rates of multi-drug resistance were observed
among enterobacteriaceae uropathogens, (87.4%). Very
high resistance was reported to ampicillin, followed by
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nia and E. coli were the principal MDR isolates. Overall
prevalence of CPE was 2.73% and all CPE strains were
100% ESBL producer and completely resistant to ampicillin,
cefotaxime, cefpodoxime, cotrimoxazole, chloramphenicol,
and amoxicillin-calvulanic acid. The only drug that shows
low resistance rate was ciprofloxacin. Being female, age,
hospitalization, and prior antibiotic use were associated risk
factors for MDRE. Therefore, efforts should be made to re-
duce patient hospital stay and maximize rational use of
drugs. Additional and vigorous investigation especially on
CPE should be encouraged.
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